An­oth­er top Genen­tech ex­ec gets poached, this time tak­ing the helm at CAR-T play­er Bel­licum

One of the best com­pa­nies you can have on your re­sume in bio­phar­ma these days is Genen­tech. The com­pa­ny is cred­it­ed with 11 new drug ap­provals since Roche took over in 2009, in­clud­ing some block­buster ad­di­tions. And the re­sult­ing ex­o­dus of tal­ent now in­cludes Rick Fair, the head of on­col­o­gy glob­al prod­uct strat­e­gy, who is tak­ing over as CEO of the im­muno-on­col­o­gy play­er Bel­licum $BLCM.

Now ex-CEO Tom Far­rell is out, rel­e­gat­ed to a tem­po­rary role as com­pa­ny ad­vis­er dur­ing the tran­si­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.